BioPharmSignal logoBioPharmSignal

Biotech News

Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance

Accelerate Diagnostics (AXDX)Accelerate DiagnosticsFDA / regulatory

AXDX (AXDX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is axdx.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

INBSIntelligent Bio Solutions2026-09-09 12:30 EST

Intelligent Bio Solutions Submits FDA 510(k) Package for Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market Clearance

INBSIntelligent Bio Solutions2026-06-02 12:30 EST

Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission

DGXQuest Diagnostics2026-08-24 11:24 EST

Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology

OSUROraSure Technologies, Inc.2026-01-05 13:00 EST

OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review

DGXQuest Diagnostics2026-06-24 12:52 EST

Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing

OSUROraSure Technologies, Inc.2026-06-11 12:00 EST

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

BJDXBluejay Diagnostics2026-08-13 10:00 EST

Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization

BIAFbioAffinity Technologies, Inc.2026-07-22 12:08 EST

bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD

BJDXBluejay Diagnostics2026-06-06 00:13 EST

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

LUCDLucid Diagnostics2026-08-05 12:46 EST

Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test

View all latest news

Accelerate Diagnostics

Accelerate Diagnostics was a diagnostics company focused on rapid infectious-disease testing before its restructuring and decline. Its platform aimed to speed up bacterial identification and susceptibility testing.

Recent company news

AXDXAccelerate Diagnostics2025-05-08 13:00 EST

Accelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All Assets

AXDXAccelerate Diagnostics2025-03-21 17:52 EST

Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance

AXDXAccelerate Diagnostics2025-03-21 12:30 EST

Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results

AXDXAccelerate Diagnostics2025-01-10 21:05 EST

Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results

AXDXAccelerate Diagnostics2024-11-07 21:05 EST

Accelerate Diagnostics Reports Third Quarter 2024 Financial Results

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
MedTech
Location
United States